Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 4

recruiting
3 974
countries
28
conditions
2 106

48 trials match your criteria

Hormone receptor positive breast cancer

Not recruiting

Study of Palbociclib as an Alternative to Chemotherapy for Older Patients with High-Risk Early Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Anastrozole

HER2 positive breast cancer

Not recruiting

Study of tucatinib, pertuzumab and trastuzumab combination for patients with HER2-positive metastatic breast cancer who have brain metastases after local therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole

Hormone receptor positive breast cancer

Not recruiting

Study of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole

Breast cancer

Not recruiting

Study of Imlunestrant, Fulvestrant, Exemestane, and Abemaciclib for Patients with Advanced Estrogen Receptor Positive, HER2 Negative Breast Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study on Metformin to Prevent High Blood Sugar in Advanced Breast Cancer Patients with Alpelisib and Endocrine Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study on Reducing Hormone Therapy Duration with Exemestane, Letrozole, and Anastrozole in Post-Menopausal Women with Low-Risk Hormone-Sensitive Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole

Breast cancer+3

Not recruiting

Study on Giredestrant and Everolimus for Patients with Estrogen Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study of palbociclib with hormone therapy guided by ESR1 mutation monitoring in patients with ER-positive, HER2-negative metastatic breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole

Breast cancer

Not recruiting

Study on Anastrozole, Letrozole, Exemestane, and Tamoxifen for Women Aged 70+ with Early Stage Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Anastrozole

Hormone receptor positive breast cancer+1

Not recruiting

Study of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study on the Effect of Tamoxifen and Chemotherapy in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer with Low Recurrence Scores

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole

Breast cancer+1

Not recruiting

Study on Early Breast Cancer Treatment with Palbociclib, Tamoxifen, and Exemestane for Patients with Estrogen Receptor Positive Tumors

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.